EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Oncolytic virus therapy for cancer

Joe Goldufsky, Shanthi Sivendran, Sara Harcharik, Michael Pan, Sebastian Bernardo, Richard H Stern, Philip Friedlander, Carl E Ruby, Yvonne Saenger, Howard L Kaufman

Oncolytic Virotherapy · 2013-09 · 31

DOI: 10.2147/ov.s38901 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncolytic Virotherapy, 2013-09. Verfasst von Joe Goldufsky und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology & Microbiology, Rush University Medical Center, Chicago IL, USA. Die Arbeit wurde bisher 17-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of oncolytic viruses to treat cancer is based on the selection of tropic tumor viruses or the generation of replication selective vectors that can either directly kill infected tumor cells or increase their susceptibility to cell death and apoptosis through additional exposure to radiation or chemotherapy. In addition, viral vectors can be modified to promote more potent tumor cell death, improve the toxicity profile, and/or generate host antitumor immunity. A variety of viruses have been developed as oncolytic therapeutics, including adenovirus, vaccinia virus, herpesvirus, coxsackie A virus, Newcastle disease virus, and reovirus. The clinical development of oncolytic viral therapy has accelerated in the last few years, with several vectors entering clinical trials for a variety of cancers. In this review, current strategies to optimize the therapeutic effectiveness and safety of the major oncolytic viruses are discussed, and a summary of current clinical trials is provided. Further investigation is needed to characterize better the clinical impact of oncolytic viruses, but there are increasing data demonstrating the potential promise of this approach for the treatment of human and animal cancers.

Schlagwörter

Stichwörter der Autor:innen

cancergene therapyoncolytic therapytreatmentvirus

Autor:innen und Institutionen

  • Department of Immunology & Microbiology, Rush University Medical Center, Chicago IL, USA.
  • Department of Hematology/Oncology Medical Specialists, Lancaster General Health, Lancaster, PA, USA.
  • Department of Medical Oncology, Tisch Cancer Institute, The Mount Sinai School of Medicine, New York, NY, USA.
  • Department of Radiology, Tisch Cancer Institute, The Mount Sinai School of Medicine, New York, NY, USA.
  • Department of Immunology & Microbiology, Rush University Medical Center, Chicago IL, USA; Department of Surgery, Rush University Medical Center, Chicago IL, USA.

Zitieren

APA

Goldufsky, J., Sivendran, S., Harcharik, S., Pan, M., Bernardo, S., Stern, R. H., Friedlander, P., Ruby, C. E., Saenger, Y., & Kaufman, H. L. (2013). Oncolytic virus therapy for cancer. Oncolytic Virotherapy, 31. https://doi.org/10.2147/ov.s38901

Vancouver

Goldufsky J, Sivendran S, Harcharik S, Pan M, Bernardo S, Stern RH, et al. Oncolytic virus therapy for cancer. Oncolytic Virotherapy. 2013:31. doi:10.2147/ov.s38901

BibTeX
@article{Goldufsky2013,
  author = {Goldufsky, Joe and Sivendran, Shanthi and Harcharik, Sara and Pan, Michael and Bernardo, Sebastian and Stern, Richard H and Friedlander, Philip and Ruby, Carl E and Saenger, Yvonne and Kaufman, Howard L},
  title = {Oncolytic virus therapy for cancer},
  journal = {Oncolytic Virotherapy},
  year = {2013},
  pages = {31},
  doi = {10.2147/ov.s38901}
}
Kostenlos starten →